✦ LIBER ✦

Recombinant human interleukin 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial

✍ Scribed by Michael Ellis; Ferdinand Zwaan; Ulla Hedström; Christopher Poynton; Jörgen Kristensen; Pauline Jumaa; Julie Wassell; Basel al-Ramadi

Book ID: 117282770
Publisher: The Lancet
Year: 2003
Tongue: English
Weight: 103 KB
Volume: 361
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(03)12322-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of ustekinumab, a hu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

✍ Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Y 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 222 KB

Efficacy and safety of ustekinumab, a hu

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

✍ Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 295 KB

Therapeutic effect of recombinant human

Therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer : A double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial

✍ Hong Gyun Wu; Si Yeol Song; Yeon Sil Kim; Young Taek Oh; Chang Geol Lee; Ki Chan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 2 views

Long-term safety and maintenance of clin

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

✍ George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 3 views

A phase II randomized, double-blind, pla

A phase II randomized, double-blind, placebo-controlled multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin: Paul J Pockros, John G McHutchison, Scripps Clinic, La Jolla, CA; Chris O'Brien, University of Miami, Miami, FL; Myron Tong, Huntingon Medical Research Institute, Pasadena, CA; Coleman Smith, Minnesota Clinical Research Center, St. Paul, MN; Vinod Rustgi, Metropolitan Research Group, Fairfax, VA; Robert L Carithers, University of Washington Medical Center, Seattle, WA; Elizabeth Olek, Genetics Institute, Cambridge, MA

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB